E Fund Management Hong Kong Co. Ltd. Trims Stock Holdings in Danaher Co. (NYSE:DHR)

E Fund Management Hong Kong Co. Ltd. cut its position in Danaher Co. (NYSE:DHR) by 6.5% during the fourth quarter, Holdings Channel reports. The firm owned 603 shares of the conglomerate’s stock after selling 42 shares during the period. E Fund Management Hong Kong Co. Ltd.’s holdings in Danaher were worth $138,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. FMR LLC boosted its position in shares of Danaher by 15.8% during the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after buying an additional 3,217,631 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in Danaher by 17.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after acquiring an additional 535,254 shares in the last quarter. International Assets Investment Management LLC boosted its holdings in Danaher by 40,196.5% during the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after acquiring an additional 428,897 shares during the period. Montrusco Bolton Investments Inc. increased its stake in Danaher by 30.4% during the third quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock worth $465,617,000 after purchasing an additional 397,671 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec lifted its position in shares of Danaher by 82.4% during the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 653,375 shares of the conglomerate’s stock worth $181,651,000 after purchasing an additional 295,187 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

NYSE DHR opened at $245.95 on Monday. The company has a fifty day moving average of $235.33 and a two-hundred day moving average of $253.54. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a 1 year low of $225.42 and a 1 year high of $281.70. The company has a market capitalization of $177.65 billion, a PE ratio of 46.94, a P/E/G ratio of 4.43 and a beta of 0.83.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. Danaher’s dividend payout ratio is presently 20.61%.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on DHR. Stephens restated an “overweight” rating and issued a $315.00 price objective on shares of Danaher in a report on Wednesday, October 23rd. Royal Bank of Canada cut their price objective on Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Bank of America upgraded Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price for the company in a report on Friday, December 13th. Raymond James cut their price target on Danaher from $300.00 to $275.00 and set an “outperform” rating on the stock in a report on Tuesday, January 21st. Finally, Evercore ISI lifted their price objective on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Six research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $285.55.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.